Epothilones in prostate cancer

Urologic Oncology
William K Kelly

Abstract

Treatment options for castration-resistant prostate cancer (CRPC) are limited. Although taxane-based regimens offer limited survival benefits, patients frequently relapse, and there are no standard regimens beyond progression. The epothilones represent a new class of chemotherapeutics that stabilize microtubules but have a distinct mechanism of action to the taxanes and low susceptibility to drug resistance. This article seeks to provide a review of what is currently known about the preclinical and clinical activity of this emerging class of agents. A literature search was conducted using PubMed and congress abstract databases to identify clinical data relevant to the epothilones and their use in CRPC. Preference was given to recently published, well-designed preclinical reports and clinical studies. Preclinical activity has been shown for several epothilones in taxane-resistant cell lines across several tumors, including CRPC. Ixabepilone, sagopilone, and patupilone have demonstrated clinical activity and tolerability in phase II CRPC trials. The epothilones have demonstrated efficacy in CRPC, and ongoing studies will help define their roles in this disease state, including optimal dosing, combination regimens, and clinical bi...Continue Reading

References

May 9, 2001·Biochimica Et Biophysica Acta·C A BurkhartS Band Horwitz
Mar 21, 2002·Nature Reviews. Cancer·Michael M GottesmanSusan E Bates
Sep 25, 2003·Annals of Oncology : Official Journal of the European Society for Medical Oncology·O SmaletzW K Kelly
Oct 8, 2004·The New England Journal of Medicine·Ian F TannockUNKNOWN TAX 327 Investigators
Oct 8, 2004·The New England Journal of Medicine·Daniel P PetrylakE David Crawford
Jan 11, 2005·The Journal of Pathology·D B Longley, P G Johnston
Apr 23, 2005·Toxicology and Applied Pharmacology·Elaine M LeslieSusan P C Cole
Jun 20, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·UNKNOWN Southwest Oncology GroupE David Crawford
Jul 21, 2006·Advances in Enzyme Regulation·James A McCubreyMassimo Libra
Oct 26, 2006·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Tateki YoshinoMikio Igawa
May 19, 2007·Clinical Breast Cancer·Xavier PivotChristian Villanueva
Jul 24, 2007·The Journal of Urology·Paul Mathew, Robert Dipaola
Oct 13, 2007·Annals of Oncology : Official Journal of the European Society for Medical Oncology·P FumoleauE Ferrant
Feb 22, 2008·CA: a Cancer Journal for Clinicians·Ahmedin JemalMichael J Thun
Mar 1, 2008·BJU International·Ronald de Wit
Mar 20, 2008·Cancer Chemotherapy and Pharmacology·Francis Y F LeeRobert Kramer
Mar 28, 2008·Expert Opinion on Investigational Drugs·Michelle Harrison, Charles Swanton

❮ Previous
Next ❯

Citations

Nov 9, 2012·The British Journal of Radiology·C O'Hanlon Brown, J Waxman
May 20, 2011·European Urology·Himisha BeltranIan F Tannock
Nov 1, 2011·BJU International·Daniel J LeeShahrokh F Shariat
May 7, 2014·Journal of Pediatric Oncology Nursing : Official Journal of the Association of Pediatric Oncology Nurses·Deborah RobinsonCheryl Rodgers
May 7, 2014·Journal of Pediatric Oncology Nursing : Official Journal of the Association of Pediatric Oncology Nurses·Alison FernbachCheryl Rodgers

❮ Previous
Next ❯

Related Concepts

Related Feeds

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.